GIS vs RNAZ · P/E 8.2, rev $18.42B vs $5.1M cap
General Mills Inc (GIS) versus Transcode Therapeutics Inc (RNAZ) — a side-by-side from cached financials, not a winner call.
General Mills Inc (GIS) is a packaged foods company listed on NYSE.
Transcode Therapeutics Inc (RNAZ) is a biotechnology company listed on NASDAQ.
Latest reported GIS revenue for 2026-05-31 was $18.42B. Net income was -$87.6M. Revenue was up 304.4% from 2025-05-25 to 2026-05-31. GIS currently screens at market cap $17.80B and trailing P/E 8.2.
RNAZ does not have a complete income-statement cache yet.
GIS currently screens at market cap $17.80B and trailing P/E 8.2. RNAZ currently screens at market cap $5.1M.
Not investment advice. Open the GIS and RNAZ stock pages for the full models.
Not investment advice.